We've found
25,125
archived clinical trials in
Diabetes
We've found
25,125
archived clinical trials in
Diabetes
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Updated: 8/1/2016
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus
Updated: 8/1/2016
A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6811135 in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated: 8/1/2016
A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus
Updated: 8/1/2016
A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6811135 in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus
Updated: 8/1/2016
A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6811135 in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated: 8/1/2016
A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus
Updated: 8/1/2016
A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6811135 in Patients With Type 2 Diabetes Mellitus.
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Updated: 8/1/2016
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 8/1/2016
Click here to add this to my saved trials